Showing 6961-6970 of 8649 results for "".
- Samsung Bioepis to Regain European Commercial Rights for Ophthalmology Biosimilars from Biogenhttps://modernod.com/news/samsung-bioepis-to-regain-european-commercial-rights-for-ophthalmology-biosimilars-from-biogen/2484299/Samsung Bioepis has entered into an Asset Purchase Agreement (APA) with Biogen concerning the transfer of two ophthalmology assets: Byooviz (ranibizumab) and Opuviz (aflibercept)—both biosimilars referencing leading treatments for retinal disea
- The Vision Council Urges Commerce Department to Exclude Optical Products from Potential Tariffshttps://modernod.com/news/the-vision-council-urges-commerce-department-to-exclude-optical-products-from-potential-tariffs/2484295/The Vision Council has submitted formal comments to the US Department of Commerce opposing potential new tariffs that could affect essential optical products and equipment. The comments respond to two ongoing Section 2
- Ophthalmic World Leaders (OWL) Names First MD President and Other Leadership Changes for 2026https://modernod.com/news/ophthalmic-world-leaders-owl-names-first-md-president-and-other-leadership-changes-for-2026/2484293/Ophthalmic World Leaders (OWL) announces the appointment of Renee Bovelle, MD, as its new President. OWL also welcomes three new members to its Board of Directors: Kevin M. Douglas, MD (Medical Director, Eye Care – Retina, AbbVie), Maáza Martin (S
- FDA Issues CRL to Sydnexis for SYD-101 in Pediatric Myopiahttps://modernod.com/news/fda-does-not-approve-sydnexis-syd-101-in-pediatric-myopia/2484210/The FDA has issued a complete response letter (CRL) for Sydnexis' new drug application (NDA) for SYD-101, a proprietary 0.01% atropine formulation designed to slow the progression of myopia in children. T
- OneSight EssilorLuxottica Foundation and Vision To Learn Extend Partnership to Expand Vision Care for Children Nationwidehttps://modernod.com/news/onesight-essilorluxottica-foundation-and-vision-to-learn-extend-partnership-to-expand-vision-care-for-children-nationwide/2484209/The OneSight EssilorLuxottica Foundation and Vision To Learn announced a 2-year extension of their 8-year partnership dedicated to providing vision care services to children in need—helping them see clearly and reach their full potential in school and be
- VEO Ophthalmics Partners with PeriVision to Bring VisionOne VR Visual Field Platform to UShttps://modernod.com/news/veo-ophthalmics-announces-us-launch-of-visionone-vr-visual-field-platform/2484203/VEO Ophthalmics announced the availability of the VisionOne VR Visual Field platform in the United States through a strategic partnership with PeriVision. This collaboration brings Switzerland-based PeriVision’s patented AI visual field-testing algorithm (SORS) to
- Virtual Vision Health Expands Virtual Eye Platform with New Diagnostic Modules and Multi-Exam Integrationhttps://modernod.com/news/virtual-vision-health-expands-virtual-eye-platform-with-new-diagnostic-modules-and-multi-exam-integration/2484191/Virtual Vision Health announced a series of upgrades to its Virtual Eye platform—a VR vision testing system designed to deliver immersive, data-driven visual field, progression analysis, and functional eye assessments.
- OcuSciences Secures CE Mark for OcuMet Beacon, Expands European Deploymenthttps://modernod.com/news/ocusciences-secures-eu-ce-clearance-for-ocumet-beacon-expands-european-deployment/2484181/OcuSciences has received CE Mark clearance for its OcuMet Beacon, a diagnostic instrument designed to enhance clinicians’ ability to assess eye health and detect retinal disorders. The CE mark signifies that the OcuMet Beacon meets the health, safet
- Tilak Receives Positive Opinion in Europe for Early Reimbursement of Odysight Telemonitoring Devicehttps://modernod.com/news/tilak-receives-positive-opinion-for-early-reimbursement-of-odysight-telemonitoring-device/2484169/Paris-based Tilak Healthcare has received a positive opinion from the French National Health Authority (Haute Autorité de Santé, HAS) for the reimbursement of Odysight under the PECAN (Prise En Charge Anticipée des dispositifs m&
- NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Modelhttps://modernod.com/news/nurexone-demonstrates-reproducible-dose-dependent-vision-recovery-in-preclinical-glaucoma-model/2484162/NurExone Biologic announced new preclinical results showing that its lead candidate ExoPTEN produces a reproducible, dose-dependent therapeutic effect in an eye model of glaucoma. The study, conducted in collaboration